Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04100473Phase 2Completed

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT03307512Phase 2Terminated

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Role: lead

NCT02716610Phase 1Completed

Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes

Role: lead

NCT02713841Phase 1Completed

Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes

Role: lead

All 4 trials loaded